Výsledky vyhledávání - "Nicolas De Sousa Carvalho"

Comparison of short course radiotherapy with chemoradiotherapy for locally advanced rectal cancers in the elderly: A multicentre, randomised, non-blinded, phase 3 trial

Autor: Eric François, Berardino De Bari, Philippe Ronchin, Elodie Nouhaud, Isabelle Martel-Lafay, Pascal Artru, Pierre Clavere, Veronique Vendrely, Valerie Boige, Deny Gargot, Claire Lemanski, Nicolas De Sousa Carvalho, Jocelyn Gal, Mandy Pernot, Nicolas Magné

Publikováno v: European journal of cancer (Oxford, England : 1990). 180

There is no specific guideline for the treatment of locally advanced rectal cancers in the elderly. Here we compared R0 resection rate and degradation of autonomy based on the instrumental activities of daily living score between neoadjuvant, short c

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2b7a6a1abaca11824c56563cdb1d9de9
https://pubmed.ncbi.nlm.nih.gov/36535196

Zobrazit plný text záznamu

Regorafenib (REG) combined with irinotecan (IRI) versus IRI alone as second-line treatment in patients with metastatic gastro-oesophageal adenocarcinomas (mGA): A randomized phase II trial (PRODIGE 58 – UCGI 35 – REGIRI)

Autor: Emmanuelle Samalin, Hélène Senellart, Ludovic Evesque, Olivier Bouché, Faiza Khemissa, Christelle De La Fouchardiere, Anthony Lopez, Slimane Dermeche, Damien Botsen, David Tougeron, Aziz Zaanan, Meher BEN Abdelghani, Emmanuel Guardiola, Olivier Dubreuil, Valérie Le Brun Ly, Audrey Hennequin, Nicolas De Sousa Carvalho, Florence Castan, Anthony Turpin

Publikováno v: Journal of Clinical Oncology. 41:387-387

387 Background: Several options have been evaluated as 2nd line treatment in mGA after failure of 1st line platinum based chemotherapy including taxanes and IRI as monotherapies or paclitaxel combined with ramucirumab but with a limited efficacy. REG

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c3033ac15a3c6557a7cd3c44f4f53e51
https://doi.org/10.1200/jco.2023.41.4_suppl.387

Zobrazit plný text záznamu

Results of randomized, placebo (PL)-controlled phase II study evaluating efficacy and safety of regorafenib (REG) in patients (pts) with metastatic osteosarcoma (metOS), on behalf of the French Sarcoma Group (FSG) and Unicancer

Publikováno v: Journal of Clinical Oncology. 36:11504-11504

11504Background: Oral multikinase inhibitor REG has shown activity in GIST and non-adipocytic soft tissue sarcomas. We designed REGOBONE as a non-comparative phase II, double-blind, PL-controlled t...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b566adecfd9cef6bcda7d6dc0bbfe817
https://doi.org/10.1200/jco.2018.36.15_suppl.11504

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání